Biogen – Rallies 60%
Biogen Inc. – Common is a current holding in our US high conviction portfolio.
The stock price rallied following the FDA decision, which was announced earlier this week, to approve Biogen’s drug Aducanumab, a treatment for Alzheimer’s disease.
